13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • 64091742PCR2001 (GALAHAD)

    Acronym: 

    GALAHAD

    ACTRN/NCT /ethics: 

    NCT02854436

    Scientific title: 

    A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase II Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Male Anticipated Start Date 2016-08-31
    Molecular Target Anticipated End Date 2019-10-10
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2016-08-31
    Anticipated End Date 2019-10-10

    Trial Summary

    The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies

    Lay Summary

    A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

    Sponsor / Cooperative group

    Janssen Research & Development LLC

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting